Physician profile
Jamil Waters
NPI 1699275255
$8,920.84
in general payments reported to CMS, 2019-2025
23 companies · $1,851 in 2025
The $1,851 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $560 · 2022: $1,737 · 2023: $1,668 · 2024: $3,105 · 2025: $1,851.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,239 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,020 · Education: $365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,239.08 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,020.00 |
| Education | $364.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $1,516.17 | 2022-2025 | Opzelura |
| Genzyme Corporation | $1,440.65 | 2021-2025 | |
| Abbvie INC. | $1,193.42 | 2021-2025 | |
| Leo Pharma INC. | $801.08 | 2021-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $759.96 | 2021-2025 | Dupixent |
| Arcutis Biotherapeutics, INC. | $483.81 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $412.78 | 2022-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $317.12 | 2021-2025 | Absorica Ld, Winlevi |
| Amgen INC. | $308.55 | 2021-2025 | Otezla, Otezla |
| Sanofi-Aventis U.S. LLC | $257.33 | 2021-2025 | |
| Galderma Laboratories, L.P. | $223.49 | 2024-2025 | Nemluvio |
| Lilly USA, LLC | $217.59 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Janssen Biotech, INC. | $200.45 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Ucb, INC. | $181.54 | 2022-2024 | Bimzelx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.81 | 2022-2025 | Spevigo |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $108.95 | 2023-2025 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $105.50 | 2022-2025 | Cabtreo |
| Journey Medical Corporation | $76.63 | 2022-2025 | |
| Pfizer INC. | $67.10 | 2022-2024 | |
| Organon LLC | $49.91 | 2025 | Vtama |
| Epi Health, LLC | $24.24 | 2022 | |
| Almirall LLC | $23.75 | 2022 | |
| Botanix Sb INC | $17.01 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamil Waters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.